Oruka Therapeutics Inc expected to post a loss of 52 cents a share - Earnings Preview

Oruka Therapeutics

21/04/2025 12:17

Oruka Therapeutics Inc ORKA.OQ ORKA.O is expected to report resultson April 23 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Oruka Therapeutics Inc is for a loss of 52 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Oruka Therapeutics Inc is $41.00​, above​ its last closing price of $9.22. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.70
-0.68
-0.49
Beat
28.1
Sep. 30 2024
-0.53
-0.40
-1.46
Missed
-263.3
​
​​
​

This summary was machine generated April 21 at 11:17 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)